Q-Line Biotech Limited, originally incorporated as POCT Services Private Limited in 2010, operates as a developer, manufacturer, and marketer of in-vitro diagnostic (IVD) products and equipment. The company transitioned to a public company in March 2025, following a name change in 2021 to align with its biotechnology focus. Since 2013, Q-Line Biotech has supplied diagnostic equipment and reagents primarily to diagnostic service providers, hospitals, and medical colleges, specializing in Clinical Chemistry, Hematology, Immunodiagnostics, Molecular Diagnostics, and Point-of-Care (POC) devices.
The company established its first manufacturing unit in New Delhi in 2016-17 and expanded its footprint by incorporating subsidiaries such as POCT Science House Private Limited in 2019 for diagnostic laboratory services. In 2023, it ventured into Radiology and Imaging Services through Q-Line Iris Private Limited. As part of its strategic restructuring, Q-Line Biotech sold its controlling stake in Q-Line Nutraceuticals Private Limited in 2025 to focus on diagnostics and acquired a new manufacturing plant in Lucknow, Uttar Pradesh.
Q-Line Biotech operates under strict regulatory oversight, with its facilities regularly inspected by authorities, including the CDSCO, State Drug Authority, and European agencies. This ensures adherence to high-quality standards in its manufacturing and product offerings. The company now aims to strengthen its market position with a fresh IPO of 7,053,200 equity shares at a face value of INR 10 each.
With a diversified product portfolio, a strong regulatory framework, and strategic expansions, Q-Line Biotech Limited is poised for growth in the IVD and diagnostics market, making it a potential opportunity for investors seeking exposure to the healthcare industry.